Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

FDA approves Abbott drug for psoriasis

Humira approved to treat psoriasis, says Abbott; extra indication could add $500M to blockbuster's sales, analyst sales.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- The FDA approved Abbott's blockbuster drug Humira for yet another indication, psoriasis, the drugmaker said Friday.

The extra indication could add at least $500 million in annual sales to Humira, which is expected to total $3 billion in 2007, said Phillip Nalbone, analyst for RBC Capital Markets, who was interviewed just prior to the announcement.

Humira was already approved to treat psoriasis in Europe. In the U.S., Humira was already approved to treat four other diseases, including rheumatoid arthritis, psoriatic arthritis, an inflammation of the digestive tract called Crohn's disease and a spinal inflammation called ankylosing spondylitis.

Abbott (ABT, Fortune 500) made the announcement after the close of trading.

Abbott is the fourth-largest U.S. drugmaker in terms of annual sales, behind Johnson & Johnson (JNJ, Fortune 500), Pfizer (PFE, Fortune 500) and Merck (MRK, Fortune 500). To top of page

Photo Galleries
Banned! 10 things you won't find in China China says it wants to open its economy more to the rest of the world, but Beijing keeps a tight grip on technology and access to media. These 10 items are still off limits. More
A morning at the AltSchool, an education startup that Silicon Valley is crazy about The AltSchool is a system of "micro schools" and an education software maker that has raised about $133 million from investors like Andreessen Horowitz and Mark Zuckerberg and Priscilla Chan's philanthropic fund. More
Coolest cars for $18,000 These are the best budget cars, according to the experts at Kelley Blue Book. More
Sponsors